Pfizer (PFE) Competitors

Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Do insiders and institutionals believe in AMGN or PFE?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.8% of Amgen shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor AMGN or PFE?

In the previous week, Pfizer had 121 more articles in the media than Amgen. MarketBeat recorded 169 mentions for Pfizer and 48 mentions for Amgen. Amgen's average media sentiment score of 1.33 beat Pfizer's score of 0.84 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	43 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	107 Very Positive mention(s)	13 Positive mention(s)	34 Neutral mention(s)	9 Negative mention(s)	5 Very Negative mention(s)	Positive

Which has higher valuation & earnings, AMGN or PFE?

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.80	$4.09B	$12.23	24.36
Pfizer	$63.63B	2.45	$8.03B	$1.88	14.56

Do analysts recommend AMGN or PFE?

Amgen presently has a consensus price target of $309.70, suggesting a potential upside of 3.96%. Pfizer has a consensus price target of $28.41, suggesting a potential upside of 3.83%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	1 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.29
Pfizer	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.37

Which has more volatility & risk, AMGN or PFE?

Amgen has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Is AMGN or PFE a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.3%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Is AMGN or PFE more profitable?

Amgen has a net margin of 18.96% compared to Pfizer's net margin of 16.84%. Amgen's return on equity of 174.71% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	18.96%	174.71%	13.12%
Pfizer	16.84%	21.42%	9.12%

Summary

Amgen beats Pfizer on 12 of the 20 factors compared between the two stocks.